EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Myxoid epithelioid smooth muscle tumor of the vulva: A distinct entity with MEF2D :: NCOA2 gene fusion

Laura M Warmke iD, Amin Mustafa, Ying S Zou, Jessica L Davis iD, Thomas M Ulbright, Sheila E Segura

Genes, Chromosomes and Cancer · 2024

DOI: 10.1002/gcc.23209 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, 2024. Verfasst von Laura M Warmke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Smooth Muscle Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Smooth muscle tumors are the most common mesenchymal tumors of the female genital tract, including the vulva. Since vulvar smooth muscle tumors are rare, our understanding of them compared to their uterine counterparts continues to evolve. Herein, we present two cases of morphologically distinct myxoid epithelioid smooth muscle tumors of the vulva with novel MEF2D :: NCOA2 gene fusion. The tumors involved 24 and 37‐year‐old women. Both tumors presented as palpable vulvar masses that were circumscribed, measuring 2.8 and 5.1 cm in greatest dimension. Histologically, they were composed of epithelioid to spindle‐shaped cells with minimal cytologic atypia and prominent myxoid matrix. Rare mitotic figures were present (1–3 mitotic figures per 10 high‐power field (HPF)), and no areas of tumor necrosis were identified. By immunohistochemistry, the neoplastic cells strongly expressed smooth muscle actin, calponin, and desmin, confirming smooth muscle origin. Next‐generation sequencing identified identical MEF2D :: NCOA2 gene fusions. These two cases demonstrate that at least a subset of myxoid epithelioid smooth muscle tumors of the vulva represent a distinct entity characterized by a novel MEF2D :: NCOA2 gene fusion. Importantly, recognition of the distinct morphologic and genetic features of these tumors is key to understanding the biological potential of these rare tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smooth Muscle TumorAdultFemaleHumansYoung AdultBiomarkers, TumorGene FusionMEF2 Transcription FactorsNuclear Receptor Coactivator 2Vulva

Stichwörter der Autor:innen

MEF2DNCOA2myxoidsmooth muscle tumorvulva

Substanzen

Biomarkers, TumorMEF2 Transcription FactorsMEF2D protein, humanNCOA2 protein, humanNuclear Receptor Coactivator 2

Autor:innen und Institutionen

  • Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, USA.

ORCID-Profile: Laura M Warmke, Jessica L Davis

Zitieren

APA

Warmke, L. M., Mustafa, A., Zou, Y. S., Davis, J. L., Ulbright, T. M., & Segura, S. E. (2024). Myxoid epithelioid smooth muscle tumor of the vulva: A distinct entity with MEF2D :: NCOA2 gene fusion. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23209

Vancouver

Warmke LM, Mustafa A, Zou YS, Davis JL, Ulbright TM, Segura SE. Myxoid epithelioid smooth muscle tumor of the vulva: A distinct entity with MEF2D :: NCOA2 gene fusion. Genes, Chromosomes and Cancer. 2024. doi:10.1002/gcc.23209

BibTeX
@article{Warmke2024,
  author = {Warmke, Laura M and Mustafa, Amin and Zou, Ying S and Davis, Jessica L and Ulbright, Thomas M and Segura, Sheila E},
  title = {Myxoid epithelioid smooth muscle tumor of the vulva: A distinct entity with MEF2D :: NCOA2 gene fusion},
  journal = {Genes, Chromosomes and Cancer},
  year = {2024},
  doi = {10.1002/gcc.23209}
}
Kostenlos starten →